Sydney E. Salmon

17.3k total citations · 7 hit papers
136 papers, 13.4k citations indexed

About

Sydney E. Salmon is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Sydney E. Salmon has authored 136 papers receiving a total of 13.4k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Molecular Biology, 51 papers in Oncology and 48 papers in Hematology. Recurrent topics in Sydney E. Salmon's work include Multiple Myeloma Research and Treatments (42 papers), Monoclonal and Polyclonal Antibodies Research (21 papers) and Cancer Treatment and Pharmacology (21 papers). Sydney E. Salmon is often cited by papers focused on Multiple Myeloma Research and Treatments (42 papers), Monoclonal and Polyclonal Antibodies Research (21 papers) and Cancer Treatment and Pharmacology (21 papers). Sydney E. Salmon collaborates with scholars based in United States, Germany and Portugal. Sydney E. Salmon's co-authors include Brian G.M. Durie, Anne W. Hamburger, Kit S. Lam, Evan M. Hersh, Richard J. Knapp, Victor J. Hruby, Wieslaw M. Kazmierski, David S. Alberts, Thomas E. Moon and B Soehnlen and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Sydney E. Salmon

135 papers receiving 12.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1975 2.4k citations Brian G.M. Durie, Sydney E. Salmon Cancer profile →
A new type of synthetic peptide library for identifying ligand-binding activity

1991 1.4k citations Kit S. Lam, Sydney E. Salmon et al. Nature profile →
Primary Bioassay of Human Tumor Stem Cells

1977 1.3k citations Sydney E. Salmon et al. profile →
Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer

2001 1.2k citations Robert C. Flanigan, Sydney E. Salmon et al. New England Journal of Medicine profile →
Quantitation of Differential Sensitivity of Human-Tumor Stem Cells to Anticancer Drugs

1978 779 citations Sydney E. Salmon, Brian G.M. Durie et al. New England Journal of Medicine profile →
Evidence for the Secretion of an Osteoclast Stimulating Factor in Myeloma

1974 502 citations Sydney E. Salmon et al. New England Journal of Medicine profile →
Primary Bioassay of Human Myeloma Stem Cells

1977 365 citations Sydney E. Salmon et al. profile →

Peers

Countries citing papers authored by Sydney E. Salmon

Since Specialization

Citations

This map shows the geographic impact of Sydney E. Salmon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sydney E. Salmon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sydney E. Salmon more than expected).

Fields of papers citing papers by Sydney E. Salmon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sydney E. Salmon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sydney E. Salmon. The network helps show where Sydney E. Salmon may publish in the future.

Co-authorship network of co-authors of Sydney E. Salmon

This figure shows the co-authorship network connecting the top 25 collaborators of Sydney E. Salmon. A scholar is included among the top collaborators of Sydney E. Salmon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sydney E. Salmon. Sydney E. Salmon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. 2001 ·PubMed ·David S. Alberts, Alton V. Hallum, (unknown), Dava J. Garcia, Mary Gleason-Guzman, Sydney E. Salmon, P. Santabárbara, Eric J. Niesor, (unknown), C. Bentzen	28
2	Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer breakdown → 2001 ·New England Journal of Medicine ·Robert C. Flanigan, Sydney E. Salmon, Brent A. Blumenstein, Scott I. Bearman, Vivek Roy, Patrick C. McGrath, J. R. Caton, Nikhil C. Munshi, E. David Crawford	1223
3	In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers 1997 ·Cancer Chemotherapy and Pharmacology ·David S. Alberts, Paul T. Fanta, Kelli L. Running, (unknown), Dava J. Garcia, (unknown), Sydney E. Salmon	51
4	High-volume cellular screening for anticancer agents with combinatorial chemical libraries: A new methodology 1996 ·Molecular Diversity ·Sydney E. Salmon, (unknown), Yu Zhao, Michal Lebl, Viktor Krchňák, (unknown), Nikolai Sepetov, Kit S. Lam	41
5	Use of Large Combinatorial Chemical Libraries for Anticancer Drug Discovery 1995 ·International Journal of Pharmacognosy ·Sydney E. Salmon, Kit S. Lam, Stephen Felder, (unknown), Joseph Schlessinger, Axel Ullrich, Viktor Krchňák, Michal Lebl	4
6	Efficacy of prednisone in refractory multiple myeloma and measurement of glucocorticoid receptors 1994 ·Investigational New Drugs ·V. D. Gupta, E. Brad Thompson, Donna Stock-Novack, Sydney E. Salmon, H. Irving Pierce, John D. Bonnet, (unknown), (unknown)	10
7	Phase II study of carboplatin (CBDCA) in refractory multiple myeloma 1994 ·Investigational New Drugs ·Bart Barlogie, John Crowley, Sydney E. Salmon, John D. Bonnet, James K. Weick, (unknown)	3
8	Multiple release of equimolar amounts of peptides from a polymeric carrier using orthogonal linkage‐cleavage chemistry 1993 ·International journal of peptide & protein research ·Michal Lebl, Marcel Pátek, Petr Kočiš, Viktor Krchňák, Victor J. Hruby, Sydney E. Salmon, (unknown)	52
9	Evaluation of amonafide in refractory and relapsing multiple myeloma 1991 ·Anti-Cancer Drugs ·(unknown), John Crowley, Sydney E. Salmon, (unknown), Thomas J. Braun, John D. Bonnet	3
10	A Southwest Oncology Group Study on the Use of a Human Tumor Cloning Assay for Predicting Response In Patients With Ovarian Cancer 1991 ·Obstetrical & Gynecological Survey ·Daniel D. Von Hoff, (unknown), Sydney E. Salmon, (unknown), (unknown), (unknown), (unknown), (unknown), R Pugh, Robert J. Belt, David S. Alberts	3
11	A southwest oncology group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer 1991 ·Cancer ·Daniel D. Von Hoff, Richard A. Kronmal, Sydney E. Salmon, (unknown), (unknown), (unknown), (unknown), (unknown), R Pugh, Robert J. Belt, David S. Alberts	54
12	A new type of synthetic peptide library for identifying ligand-binding activity breakdown → 1991 ·Nature ·Kit S. Lam, Sydney E. Salmon, Evan M. Hersh, Victor J. Hruby, Wieslaw M. Kazmierski, Richard J. Knapp	1449
13	Phase II study of Fludarabine Phosphate in multiple myeloma 1990 ·Investigational New Drugs ·Eric H. Kraut, John J. Crowley, Michael R. Grever, (unknown), John D. Bonnet, (unknown), Sydney E. Salmon	32
14	A phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma 1990 ·Investigational New Drugs ·Mark Edelstein, John J. Crowley, Fred Valeriote, John D. Bonnet, (unknown), (unknown), Sydney E. Salmon, (unknown)	3
15	Relation of Cytogenetic Abnormalities and Clinical Outcome in Metastatic Melanoma 1990 ·New England Journal of Medicine ·Jeffrey M. Trent, Frank L. Meyskens, Sydney E. Salmon, Kay Ryschon, Stanley P. L. Leong, John R. Davis, Daniel McGee	72
16	Aclacinomycin A in the treatment of multiple myeloma: A Southwest Oncology Group study 1990 ·Investigational New Drugs ·Chatchada Karanes, John Crowley, (unknown), Bill L. Tranum, William J. Hicks, John D. Bonnet, Lyubica Dabich, Bruce W. Dana, Sydney E. Salmon	3
17	Increased peripheral blood leukocyte cytotoxic activity in cancer patients during the continuous intravenous administration of recombinant human tumor necrosis factor 1989 ·Journal of Clinical Immunology ·(unknown), (unknown), Sydney E. Salmon, Evan M. Hersh, Philip Scuderi	6
18	Controlled Studies of a New Microprocessor-Based Portable Infusion Pump 1986 ·PubMed ·Robert T. Dorr, Sydney E. Salmon, Mary E. Marsh, (unknown)	3
19	Immunotherapy of Cancer: Present Status of Trials in Man 1977 ·Cancer Research ·Sydney E. Salmon	158
20	Polyamines as markers of response and disease activity in cancer chemotherapy. 1977 ·PubMed ·Brian G.M. Durie, Sydney E. Salmon, Diane H. Russell	170

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact